首页> 外国专利> SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS

SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS

机译:脱氧尿苷类似物协同增强癌细胞中5-氟尿嘧啶的细胞毒性

摘要

In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2'-deoxyuridine (fdU or foUdR) or a 5-formyl-2'-deoxyuridine derivative, optionally in combination with 5-hydroxy-2'-deoxyuridine (hUdR); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-FU), a 5-FU prodrug (e.g. 5- fluoro-2'-deoxyuridine (FdU)) or 5-FU metabolite. In a preferred embodiment, a subject who suffers from colorectal cancer (CRC) or metastatic colorectal cancer (mCRC) is treated with a therapeutically-effective amount of fdU and either 5-FU or the 5-FU prodrug 5-fluoro-2'- deoxyuridine (FdU). Related pharmaceutical compositions are also provided.
机译:在一个实施方案中,本发明提供了一种通过对受试者施用治疗有效量的(a)5-甲酰基-2'-来治疗患有肿瘤(包括癌症,例如放射治疗抗性癌症)的受试者的方法。脱氧尿苷(fdU或foUdR)或5-甲酰基-2'-脱氧尿苷衍生物,任选与5-羟基-2'-脱氧尿苷(hUdR)组合; (b)至少一种选自5-氟尿嘧啶(5-FU),5-FU前药(例如5-氟-2'-脱氧尿苷(FdU))或5-FU代谢物的组合物。在一个优选的实施方案中,患有结直肠癌(CRC)或转移性结直肠癌(mCRC)的受试者用治疗有效量的fdU和5-FU或5-FU前药5-氟-2'-治疗。脱氧尿苷(FdU)。还提供了相关的药物组合物。

著录项

  • 公开/公告号WO2015142867A1

    专利类型

  • 公开/公告日2015-09-24

    原文格式PDF

  • 申请/专利权人 STC.UNM;IDE HIROSHI;

    申请/专利号WO2015US20991

  • 发明设计人 TOMKINSON ALAN EDWARD;MATSUMOTO YOSHIHIRO;

    申请日2015-03-17

  • 分类号A61K31/506;A61K31/513;A61K31/7072;A61P35/00;

  • 国家 WO

  • 入库时间 2022-08-21 15:04:08

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号